FI943024A - Kantasoluja estävät proteiinit - Google Patents

Kantasoluja estävät proteiinit Download PDF

Info

Publication number
FI943024A
FI943024A FI943024A FI943024A FI943024A FI 943024 A FI943024 A FI 943024A FI 943024 A FI943024 A FI 943024A FI 943024 A FI943024 A FI 943024A FI 943024 A FI943024 A FI 943024A
Authority
FI
Finland
Prior art keywords
stem cells
inhibiting stem
proteins inhibiting
proteins
cells
Prior art date
Application number
FI943024A
Other languages
English (en)
Swedish (sv)
Other versions
FI943024A0 (fi
Inventor
Stewart Craig
Michael George Hunter
Richard Mark Edwards
Lloyd George Czaplewski
Richard James Gilbert
Original Assignee
British Bio Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919127319A external-priority patent/GB9127319D0/en
Priority claimed from GB929221587A external-priority patent/GB9221587D0/en
Application filed by British Bio Technology filed Critical British Bio Technology
Publication of FI943024A0 publication Critical patent/FI943024A0/fi
Publication of FI943024A publication Critical patent/FI943024A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/523Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI943024A 1991-12-23 1994-06-22 Kantasoluja estävät proteiinit FI943024A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919127319A GB9127319D0 (en) 1991-12-23 1991-12-23 Modified proteins
GB929221587A GB9221587D0 (en) 1992-10-14 1992-10-14 Modified proteins
PCT/GB1992/002390 WO1993013206A1 (en) 1991-12-23 1992-12-23 Stem cell inhibiting proteins

Publications (2)

Publication Number Publication Date
FI943024A0 FI943024A0 (fi) 1994-06-22
FI943024A true FI943024A (fi) 1994-06-22

Family

ID=26300071

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943024A FI943024A (fi) 1991-12-23 1994-06-22 Kantasoluja estävät proteiinit

Country Status (10)

Country Link
US (2) US6057123A (fi)
EP (1) EP0627003A1 (fi)
JP (1) JPH07502404A (fi)
AU (1) AU679436B2 (fi)
CA (1) CA2125985C (fi)
FI (1) FI943024A (fi)
HU (2) HUT69788A (fi)
NO (1) NO942380L (fi)
NZ (1) NZ246354A (fi)
WO (1) WO1993013206A1 (fi)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308060D0 (en) * 1993-04-19 1993-06-02 Cancer Res Campaign Tech Stem cell inhibitor
GB9312344D0 (en) * 1993-06-15 1993-07-28 British Bio Technology Pharmaceutical formulations
US5728377A (en) * 1993-07-20 1998-03-17 Board Of Regents, The University Of Texas System Methods and compositions incorporating IP-10
AU680714B2 (en) * 1993-12-24 1997-08-07 Wolf-Georg Forssmann Human circulating cytokine CC-1
GB9517014D0 (en) * 1995-08-19 1995-10-25 British Biotech Pharm Haematopoietic recovery
US5786335A (en) * 1995-11-06 1998-07-28 Warner-Lambert Company Sulfhydryl containing peptides for treating vascular disease
GB9600559D0 (en) * 1996-01-11 1996-03-13 British Biotech Pharm Use of chemokines
WO1998013495A1 (en) * 1996-09-25 1998-04-02 British Biotech Pharmaceuticals Limited Human rantes mutants incapable of aggregate formation
US6121023A (en) * 1998-01-22 2000-09-19 Akzo Nobel N.V. Isothermal transcription based assay for the detection and quantification of the chemokine rantes
AU762472B2 (en) 1998-03-13 2003-06-26 University Of British Columbia, The Therapeutic chemokine receptor antagonists
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP3299452A1 (en) 2000-12-06 2018-03-28 Anthrogenesis Corporation Method of collecting placental stem cells
CA2438153C (en) 2001-02-14 2015-06-02 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US6515001B2 (en) 2001-03-05 2003-02-04 Chemokine Therapeutic Corporation IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
ATE421974T1 (de) 2001-12-17 2009-02-15 Serono Lab Chemokine mutanten, die als chemokine antagonisten wirken
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
MXPA04011851A (es) * 2002-05-30 2005-03-31 Celgene Corp Metodos para utilizar inhibidores de jnk o mkk para modular diferenciacion de celula y para tratar desordenes mieloproliferativos y sindromes mielodispl??sticos.
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
WO2004047770A2 (en) 2002-11-26 2004-06-10 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
US7662781B2 (en) * 2005-01-31 2010-02-16 Eci, Inc. Immunopotentiating agent
MX343814B (es) 2005-10-13 2016-11-24 Anthrogenesis Corp Inmunomodulación usando celulas madre de la placenta.
KR20080081088A (ko) 2005-12-29 2008-09-05 안트로제네시스 코포레이션 태반 줄기세포와 제2 세포원으로부터 얻은 줄기세포의 공동배양
DK2471903T3 (en) 2005-12-29 2018-05-28 Anthrogenesis Corp Placenta stem cell populations
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
SI2120977T1 (sl) 2007-02-12 2014-01-31 Anthrogenesis Coroporation Zdravljenje vnetnih bolezni z uporabo placentarnih matičnih celic
TWM322542U (en) * 2007-05-23 2007-11-21 Universal Scient Ind Co Ltd Testing machine
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
NZ617412A (en) 2007-09-28 2015-06-26 Anthrogenesis Corp Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
PE20110399A1 (es) * 2008-08-20 2011-06-22 Anthrogenesis Corp Tratamiento de la apoplejia utilizando celulas placentarias aisladas
AU2009283216B2 (en) 2008-08-20 2015-04-02 Celularity Inc. Improved cell composition and methods of making the same
RU2011110736A (ru) 2008-08-22 2012-09-27 Антродженезис Корпорейшн (Us) Способы и композиции для лечения костных дефектов с помощью плацентарных клеточных популяций
BRPI0922184A2 (pt) 2008-11-19 2020-08-18 Anthrogenesis Corporation célula isolada, população isolada de células, matriz ou estrutura sintética permanente ou decelularizada degradável, e , método para tratar um indivíduo
NZ619359A (en) * 2009-07-02 2015-07-31 Anthrogenesis Corp Method of producing erythrocytes without feeder cells
EP2529007B1 (en) 2010-01-26 2017-07-12 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
KR20220015489A (ko) 2010-04-07 2022-02-08 셀룰래리티 인코포레이티드 태반 줄기 세포를 사용한 혈관신생
CN102933221A (zh) 2010-04-08 2013-02-13 人类起源公司 使用胎盘干细胞治疗结节病
BR112013000822B1 (pt) 2010-07-13 2021-02-23 Anthrogenesis Corporation Método in vitro em duas etapas para a produção de uma população decélulas exterminadoras naturais (nk) ativadas
EP2658557A1 (en) 2010-12-31 2013-11-06 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
CN104220081A (zh) 2011-06-01 2014-12-17 人类起源公司 利用胎盘干细胞治疗疼痛
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
CN115282165A (zh) 2013-02-05 2022-11-04 细胞结构公司 来自胎盘的自然杀伤细胞
KR102682118B1 (ko) 2016-04-29 2024-07-08 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
WO2020014298A1 (en) 2018-07-10 2020-01-16 Rush University Medical Center Use of immunomodulators to control infection and stimulate healing in normal and diabetic wounds
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929555A (en) * 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
DK0494268T4 (da) * 1989-09-25 1999-11-08 Genetics Inst Fremgangsmåde til inhibering af stamcellers vækst
JPH03228683A (ja) * 1989-12-20 1991-10-09 Chemo Sero Therapeut Res Inst 生理活性ペプチドLD78α、LD78βおよびその製法、これに用いる組換えプラスミド
DE69130981D1 (de) * 1990-09-14 1999-04-15 Chiron Corp Expression von makrophagen-induzierbaren proteinen (mips) in hefezellen

Also Published As

Publication number Publication date
AU3260493A (en) 1993-07-28
HU9401902D0 (en) 1994-09-28
FI943024A0 (fi) 1994-06-22
AU679436B2 (en) 1997-07-03
WO1993013206A1 (en) 1993-07-08
NO942380D0 (fi) 1994-06-22
US6057123A (en) 2000-05-02
US5856301A (en) 1999-01-05
HUT69788A (en) 1995-09-28
NZ246354A (en) 1995-10-26
EP0627003A1 (en) 1994-12-07
CA2125985A1 (en) 1993-07-08
NO942380L (no) 1994-08-23
CA2125985C (en) 2001-04-17
JPH07502404A (ja) 1995-03-16
HU211605A9 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
FI943024A0 (fi) Kantasoluja estävät proteiinit
NO982350D0 (no) Stamcellefaktor
NO920388L (no) Tilbakeslagsventil
DK91192D0 (da) Protein
NO942066L (no) Peptidderivater
DK540289A (da) Protein
FR2632154B1 (fr) Moissonneuse
DE69415775D1 (de) Verbesserte Stielzusammensetzung
FI925636A0 (fi) Katod foer anvaendning i en elektrolytisk cell
DK132892D0 (da) Proteiner
DK197989A (da) Peptidanaloger
DE69406926D1 (de) Cholesterinreduzierte eier
DE69209522D1 (de) Tracheostomventile
FI934588A0 (fi) Insulinlik vaextfaktor bindande protein haerstammande fraon maenniskoben
KR900700503A (ko) 펩티드
DE59206308D1 (de) Schaftprothese
AT397701B (de) Vorrangumschaltventil
BR9102220A (pt) Valvula de retencao
DK0505600T3 (da) Ventilindretning
UA23018C2 (uk) Криголам
DK139193D0 (da) Rektangulaer aegbakke
ITMI920274A1 (it) Valvola
DK120792D0 (da) Protein
KR930014827U (ko) 밸브구조
KR950010621U (ko) 낚시찌

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: BRITISH BIOTECH PHARMACEUTICALS LIMITED